Literature DB >> 18848500

Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita.

U Tayal, J Burton, C Dash, F Wojnarowska, H Chapel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18848500     DOI： 10.1016/j.clim.2008.08.003

Source DB:  PubMed          Journal:  Clin Immunol        ISSN： 1521-6616            Impact factor:   3.969


× No keyword cloud information.
  4 in total

Review 1.  Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home.

Authors:  Mary Lucas; Ken Hugh-Jones; Angela Welby; Siraj Misbah; Peter Spaeth; Helen Chapel
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 2.  Bringing immunoglobulin knowledge up to date: how should we treat today?

Authors:  S Misbah; T Kuijpers; J van der Heijden; B Grimbacher; D Guzman; J Orange
Journal:  Clin Exp Immunol       Date:  2011-07-15       Impact factor: 4.330

3.  Epidermolysis bullosa acquisita with moderately severe Dysphagia due to esophageal strictures.

Authors:  Jenny Tu; Prasad W Kumarasinghe
Journal:  Indian J Dermatol       Date:  2011-03       Impact factor: 1.494

Review 4.  The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature.

Authors:  Soheil Tavakolpour
Journal:  J Res Med Sci       Date:  2016-06-14       Impact factor: 1.852
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.